The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and
hyperactivation, highlights the potential of immune renormalization as a promising strategy …

Clinical responses to checkpoint inhibitors used for cancer immunotherapy seemingly
require the presence of αβT cells that recognize tumour neoantigens, and are therefore …

Objectives Autologous chimeric antigen receptor (CAR) αβ T‐cell therapies have
demonstrated remarkable antitumor efficacy in patients with haematological malignancies; …

A growing number of studies have shown that γδ T cells play a pivotal role in mediating the
clearance of tumors and pathogen-infected cells with their potent cytotoxic, cytolytic, and …

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) was the first successful
therapy for patients with haematological malignancies, predominantly owing to graft-versus …

Allogeneic hematopoetic stem cell transplantation (HCT) offers an option for patients with
hematologic malignancies, in whom conventional standard therapies failed or are not …

Microbial diversity is associated with improved outcomes in recipients of allogeneic
hematopoietic cell transplantation (allo-HCT), but the mechanism underlying this …

Anti-T-cell lymphocyte globulin (ATLG) and posttransplant cyclophosphamide (PTCy) are
now widely used strategies to prevent graft-versus-host disease (GVHD) after allogeneic …

Allogeneic (allo) hematopoietic cell transplantation (HCT) is the only curative treatment
option for patients suffering from chemotherapy-refractory or relapsed hematological …

Background Adoptive immunotherapy is gaining momentum to fight malignancies, whereby
γδ T cells have received recent attention as an alternative cell source as to natural killer cells …